Vivos Therapeutics, Inc. (VVOS): debt financing — Vivos Therapeutics issues $2.09M unsecured note, net proceeds $1.5M, weekly $70K payments

Vivos Therapeutics, Inc.

Principal amount $2,093,340; net proceeds ~$1,500,000 after $587,340 OID and $6,000 fees.
Weekly payments of $69,778 start December 12, 2025; full prepay by Jan 4, 2026 reduces balance by $286,140.
Note is unsecured, no interest unless default; subsidiary Airway Integrated Management guarantees obligations.
Proceeds for working capital and general corporate purposes; no placement agent used.
Lender Avondale Capital is affiliate of Streeterville Capital (prior senior secured loan from June 2025).

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Vivos Therapeutics, Inc. incurred loan of $2,093,340 with Avondale Capital, LLC at does not bear interest maturing not stated.

Instrument: loan
Principal: $2,093,340
Counterparty: Avondale Capital, LLC
Rate: does not bear interest
Maturity: not stated
Event: incurrence

Exact text from the filing

On December 5, 2025, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a Note Purchase Agreement (the “ Note Purchase Agreement ”) with from Avondale Capital, LLC, a Utah limited liability company (“ Lender ”), pursuant to which the Company issued and sold to Lender a Promissory Note (the “ Note ”) in the original principal amount of $2,093,340

View on SEC.gov

312 debt financings filed in the last 30 days. Browse all debt financings →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-026438

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.